J Korean Med Sci. 2022;37(6):e48.

Eltrombopag for Post-Transplant Poor Graft Function in East Asian Patients.

, , , , , , ,

제1저자 안현진 · 교신저자 변자민, 김인호

PMID 35166084 PMC8845101 DOI 10.3346/jkms.2022.37.e48 IF 3.2 혈액종양내과

소속 (3)

Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea.
Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea. jaminbyun@naver.com.
Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea. ihkimmd@snu.ac.kr.

Abstract

Poor graft function (PGF) is a serious, potentially life-threatening complication of allogeneic hematopoietic stem cell transplantation. Eltrombopag has shown multilineage responses in patients with refractory severe aplastic anemia, supporting the idea that it may improve cytopenia in patients with PGF. This retrospective, single center analysis included 8 Korean patients receiving eltrombopag for PGF. Median interval between transplant and eltrombopag treatment was 73 days, and the median duration treatment was 3.5 weeks. With median maximum daily dose of 50 mg, the time to best response was 93 days. Median hemoglobin increased from 8.2 g/dL to 10.9 g/dL, platelet from 18.5 × 10⁹/L to 54 × 10⁹/L, and absolute neutrophil count from 1.25 × 10⁹/L to 3.32 × 10⁹/L. In conclusion, eltrombopag is a good option for PGF in Korean patients, even at a lower dose compared to western patients.

Keywords

EltrombopagPoor Graft Function

Figures

**Fig. 1** Complete blood cell count before and after eltrombopag treatment. (A) Median hemoglobin concentration increased from 8.2 g/dL to 10.9 g/dL. (B) Median absolute neutrophil count from 1.25 × 10⁹/L to 3.32 × 10⁹/L. (C) Median platelet increased from 18.5 × 10⁹/L to 54 × 10⁹/L.

그림 출처: PubMed Central 공개 논문 (PMC8845101)

Conflict of interest statement

The authors have no potential conflicts of interest to disclose.

그 밖의 정보